Drugs / KY-0118
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06175780 | Dec 2022 → Dec 2025 | neoplasm | Novatim Immune Therapeutics (Zhejiang) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KY-0118 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06175780 ↗ |
| Route | Intravenous | “injected intravenously” NCT06175780 ↗ |